Search This Blog

Friday, February 22, 2019

Sage Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Yatin Suneja initiated Sage Therapeutics with a Buy rating and $205 price target, as he believes Zulresso and SAGE-217 have generated impressive data in PPD and MDD. The analysts, who thinks those drugs “have the potential to change the treatment paradigm for treating mood disorders,” projects Zulresso and SAGE-217 could generate sales in the $3B-$5B range.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.